Detalhe da pesquisa
1.
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Lancet Oncol
; 25(4): 474-487, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547892
2.
Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.
Cell Commun Signal
; 20(1): 4, 2022 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34998412
3.
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
BMC Cancer
; 17(1): 199, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28302091
4.
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.
J Cancer Res Clin Oncol
; 146(3): 605-619, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32036454
5.
Reprocessing and sterilization of single-use electrophysiological catheters: removal of organic carbon and protein surface residues.
J AOAC Int
; 92(4): 1165-73, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19714986
6.
Comparison of performance characteristics between new and reprocessed electrophysiology catheters.
J Interv Card Electrophysiol
; 17(2): 77-83, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17226083
7.
A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.
Oncotarget
; 7(48): 78577-78590, 2016 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27713176